Delivery Order SPE2DB20D3103-SPE2DB23FN7U2

Award Date 6/22/23
Potential Completion Date 6/23/23
Potential Value $2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,632.39, is a Firm Fixed Price Delivery Order for the supply of KONVOMEP 2-84 MG/ML ORAL SUSP 300ML, a pharmaceutical product. The contract has a performance period through March 11, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,060.00 firm-fixed-price delivery order is for the supply of 4562192687 KONVOMEP 2-84 MG/ML ORAL SUSP 150ML, with a completion date of September 18, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
This federal contract award is a delivery order valued at $1,675.48 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of KONVOMEP 2-84 MG/ML ORAL SUSP 150ML, a pharmaceutical product. The order has a firm fixed price and is set to be completed by November 20, 2024. AmerisourceBergen Drug Corp, a for-profit organization, holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $2,508.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4563348772 KONVOMEP 2-84 MG/ML ORAL SUSP 150ML, with a completion date of January 18, 2024. The contract is a Delivery Order on a Firm Fixed Price basis, with no set-aside designation indicated. Amerisourcebergen holds a significant Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,931.72 firm-fixed-price delivery order is for the medical product "KONVOMEP 2-84 MG/ML ORAL SUSP 300ML" and has a completion date of February 21, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,667.52, is for the delivery of KONVOMEP 2-84 MG/ML ORAL SUSP 150ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of March 12, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,975.26, is for the delivery of KONVOMEP 2-84 MG/ML ORAL SUSP 150ML, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 7, 2025. This award is not associated with a set-aside program. AmerisourceBergen holds...
This is a $9,480.42 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of KONVOMEP 2-84 MG/ML ORAL SUSP 300ML, a pharmaceutical product, with a period of performance through March 14, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,617.52 delivery order is for the oral suspension medication Konvomep 2-84 mg/ml, with a completion date of September 13, 2024. The contract is a firm fixed-price delivery order without any set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This is a Firm Fixed Price Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of KONVOMEP 2-84 MG/ML ORAL SUSP 300ML, a pharmaceutical product, with a ceiling value of $2,965.91 and a performance period through January 24, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB23FN7U2
    Delivery Order

This federal contract award, with a ceiling value of $2,040.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a Firm Fixed Price Delivery Order for the supply of the drug KONVOMEP 2-84 MG/ML ORAL SUSP 300ML, with a completion date of June 23, 2023.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 2/27/25, 10:16 AM